Stockscreener 앱 받기
7.10
0.85%
0.06
Precision Biosciences Inc 주식(DTIL)의 최신 뉴스
Precision BioSciences to present DMD gene therapy data at May conference - Investing.com UK
Precision BioSciences (DTIL) Presents Promising Data on PBGENE-D - GuruFocus
Gene-editing trial update points to fewer crises in 7 infants - Stock Titan
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting - Yahoo! Finance Canada
Should you buy Precision BioSciences (DTIL) after golden cross? - MSN
Precision BioSciences Announces Grant of Inducement Awards under Nasdaq Listing Rule 5635(4) - marketscreener.com
Precision BioSciences (DTIL) surpasses Q4 earnings and revenue estimates - MSN
Precision BioSciences announces grant of inducement awards - TipRanks
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The National Law Review
Precision BioSciences (DTIL) Grants Inducement Award to New Empl - GuruFocus
DTIL Stock Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026 - Business Wire
Empery Asset Management, LP Reduces Stake in Precision BioSciences Inc - GuruFocus
DTIL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Precision BioSciences stock (US74019P1084): Is its gene-editing platform strong enough to unlock bio - AD HOC NEWS
Precision BioSciences reports encouraging muscle improvements in preclinical DMD gene therapy study - MSN
Precision BioSciences stock (US74019P1084): Is its gene editing platform strong enough to unlock bio - AD HOC NEWS
DTIL Assumed by Jones Trading -- Price Target Announced at $30 - GuruFocus
Short Interest in Precision BioSciences, Inc. (NASDAQ:DTIL) Decreases By 16.2% - MarketBeat
JonesTrading Reiterates Buy Rating for Precision BioSciences (NASDAQ:DTIL) - MarketBeat
JonesTrading Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Jones Trading initiates Precision BioSciences stock coverage with buy rating - Investing.com UK
Jones Trading initiates Precision BioSciences stock coverage with buy rating By Investing.com - Investing.com South Africa
Hepatitis B: Updates from Aligos Therapeutics, Arbutus Biopharma Corporation and Precision BioSciences - European AIDS Treatment Group
Precision BioSciences Expands ELIMINATE-B Trial to Europe - National Today
Precision BioSciences (DTIL) Expands Hepatitis B Trial to Europe - GuruFocus
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries - BioSpace
Empery Asset Management, Ryan M. Lane (DTIL) disclose 7.63% ownership - Stock Titan
Precision BioSciences Expands Eliminate-B Trial for Pbgene-Hbv In France And Romania - marketscreener.com
Should You Buy Precision BioSciences (DTIL) After Golden Cross? - Yahoo Finance
DTIL Options Volatility — NASDAQ:DTIL - TradingView
DTIL Options Chain — NASDAQ:DTIL - TradingView
Jobs Data: How does Precision BioSciences Inc compare to its peersStock Surge & Verified High Yield Trade Plans - baoquankhu1.vn
How does Precision BioSciences Inc compare to its peersWeekly Market Summary & AI Forecasted Stock Moves - baoquankhu1.vn
DTIL Price Today: Precision BioSciences, Inc. Stock Price, Quote & Chart - MEXC
Precision BioSciences to Attend Healthcare Conference - National Today
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference - BioSpace
Precision BioSciences (NASDAQ: DTIL) details equity plan, charter change in 2026 proxy - Stock Titan
DTIL Stock Price, Quote & Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
0.29%
0.00%
자본화:
|
볼륨(24시간):